ArticleIUBMB life2026
Non-Telomeric Role of RAP1 in Facilitating NF-κB Activation and Driving Hepatocellular Carcinoma Progression.
Article in IUBMB life, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
RAP1 (TERF2IP) is a component of the shelterin complex that protects telomeric DNA and preserves chromosome stability. In addition to its telomeric function, accumulating evidence indicates that mammalian RAP1 also exerts multiple extra-telomeric functions. Notably, RAP1 has been reported to regulate the NF-κB signaling pathway and to function as a transcriptional regulator, suggesting potential roles in tumorigenesis. In this study, we found that RAP1 expression was significantly upregulated in hepatocellular carcinoma (HCC) cells. Functional analyses demonstrated that RAP1 promoted malignant phenotypes in HCC through a non-telomeric mechanism. In cellular models, RAP1 overexpression enhanced cell proliferation while suppressing senescence and apoptosis, whereas RAP1 knockdown produced the opposite effects. Mechanistically, RAP1 functioned as an upstream activator of the NF-κB signaling cascade, resulting in increased phosphorylation of the p65 subunit and upregulation of downstream targets, including IL-1β and BCL-2. Importantly, the oncogenic activity of RAP1 was shown to be dependent on NF-κB signaling in vivo, as pharmacological inhibition of NF-κB significantly suppressed RAP1-driven tumor growth in a xenograft model. Collectively, these findings reveal a previously unrecognized role for RAP1 in promoting HCC progression through activation of NF-κB signaling and identify the RAP1/NF-κB axis as a potential therapeutic target for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.